secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELI LILLY & Co (LLY)
CIK:        0000059478
Form:       8-K
Filed at:   2024-02-06T23:59:59+00:00
Accession:  0000059478-24-000032
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lilly Q4 revenue up 28% to $9.35B; EPS $2.42 reported, $2.49 non-GAAP; FY2024 guidance issued
--------------------------------------------------------------------------------

- Q4 revenue $9,353.4M (+28% YoY); reported EPS $2.42 (+13%); non-GAAP EPS $2.49 (+19%).
- New Products (Mounjaro, Zepbound) generated $2.49B revenue, up $2.19B YoY; Growth Products $5.27B (+9%).
- 2024 guidance: revenue $40.4–41.6B; EPS $11.80–12.30; non-GAAP EPS $12.20–12.70.
- Pipeline: Zepbound and Jaypirca approved; tirzepatide Phase 2 NASH met primary endpoint; Verzenio Phase 3 mCRPC failed.
- Acquisitions of POINT Biopharma and Mablink Biosciences closed; dividend raised 15% for 6th consecutive year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/59478/000005947824000032/0000059478-24-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/59478/000005947824000032/lly-20240206.htm
  HTML page:      https://secwatch.observer/filing/0000059478-24-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer